Connect with us

Technology

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Published

on

LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates.

To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company’s ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s or its partners’ research and development projects or clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-host-third-quarter-2024-financial-results-conference-call-on-november-7-2024-302291883.html

SOURCE ADC Therapeutics SA

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Persperity Health Secures $1 Million to Revolutionize Women’s Health with Breakthrough Sweat-Sensing Technology

Published

on

By

Caltech Spin-Out Aims to Empower Women with Non-Invasive Hormone Monitoring

LOS ANGELES, Oct. 31, 2024 /PRNewswire/ — Persperity Health, Inc., a new company spun out of Caltech, announced today it has raised $1 million in pre-seed funding to accelerate the development of its groundbreaking sweat-sensing technology, set to transform women’s health by providing real-time, non-invasive hormonal insights. Led by Freeflow Ventures with participation from Caltech, Wilson Hill Ventures, Heritage Group, and ATMA Capital, this investment underscores the revolutionary potential of Persperity’s platform to redefine personalized health monitoring.

Persperity Health’s technology brings non-invasive hormone monitoring to women, empowering personalized health insights.

Exclusively licensed from Caltech and developed by Dr. Wei Gao and Dr. Cui Ye, Persperity Health’s advanced technology enables real-time hormone monitoring through device-based sweat analysis. This innovation grants women unprecedented access to personalized health data, fundamentally changing how they and their providers can manage fertility and menopause care.

“If you look at what’s commercially available, devices can track heartbeat and steps, but they aren’t capable of studying your health at a molecular level,” said Dr. Wei Gao, co-founder and inventor of the core technology at Persperity Health. “By analyzing sweat, our device provides detailed information about what’s happening inside your body. Once you realize the potential of sweat for health monitoring, it’s hard to go back to conventional methods.”

Sweat contains a wealth of information about hormonal health, including critical hormones like estradiol, progesterone, and luteinizing hormone (LH), which are vital to women’s reproductive health and overall well-being. Persperity’s technology leverages a non-invasive process called iontophoresis to induce sweat on demand, allowing women to monitor their hormone levels anytime, anywhere—without strenuous exercise or invasive procedures.

Persperity Health is also proud to announce its involvement in a prestigious $3 million ARPA-H Spark Award aimed at accelerating innovation in women’s health. Spearheaded by Principal Investigator Dr. Wei Gao at Caltech, the project was one of only 23 awardees selected from over 1,700 global applicants to advance a wearable sweat-sensing system for chronic pain assessment, especially benefiting women.

Dr. Pauline M. Maki, a renowned expert in women’s cognitive health and menopause and a co-investigator on the grant, emphasized the project’s significance, stating: “This innovative technology has the potential to transform women’s health research by enabling, for the first time, the non-invasive collection of biological markers in sweat, including estrogen—a crucial factor in numerous health conditions that disproportionately affect women, such as migraine.”

Dr. Heather Lukas, co-founder and Chief Scientific Officer at Persperity Health, highlighted the broader implications: “We’re not just creating another wearable device; we’re unlocking a new dimension of personalized health monitoring. By making the invisible visible, we’re empowering women to understand their bodies like never before. This is more than a technological advancement—it’s a revolution in women’s health.”

With the infusion of new capital, Persperity Health will accelerate product development, pursue strategic partnerships, and navigate the regulatory approval process. The company’s long-term vision includes expanding its platform to analyze additional biomarkers, with potential applications in mental health, stress management, and early detection of other women’s health issues.

About Persperity Health
Persperity Health is at the forefront of health technology innovation, pioneering sweat-sensing technology to revolutionize continuous health monitoring. Focused on women’s health, the company’s platform delivers real-time, actionable insights into hormonal health, fertility, and menopause. Led by co-founders CEO Shiv Shukla, Dr. Wei Gao, and Dr. Heather Lukas, with clinical collaborator Dr. Pauline Maki, Persperity Health is dedicated to improving how women monitor their health with non-invasive, personalized solutions.

Contact Information
Shiv Shukla
CEO, Persperity Health
press@persperityhealth.com
(818) 466-0080
https://persperityhealth.com/

For more information about Persperity Health and its mission to revolutionize women’s health, visit persperityhealth.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/persperity-health-secures-1-million-to-revolutionize-womens-health-with-breakthrough-sweat-sensing-technology-302293044.html

SOURCE Persperity Health, Inc.

Continue Reading

Technology

Local Government Information Systems (LOGIS) selects SpryPoint as Utility Solutions provider to enhance customer experience for their members

Published

on

By

SpryPoint has been selected by Local Government Information Systems (LOGIS) to provide its comprehensive suite of utility software solutions. This partnership aims to significantly enhance customer service and improve operational efficiency for LOGIS members, empowering Minnesota’s local governments with the tools needed to better serve their communities.

CHARLOTTETOWN, PE, Oct. 31, 2024 /PRNewswire-PRWeb/ — SpryPoint, a leading provider of cloud-native utility software solutions, is pleased to announce that it has been selected by Local Government Information Systems (LOGIS) to provide its organization members with SpryPoint’s comprehensive utility software suite. This offering enables LOGIS members to improve both customer service and utility operations and includes SpryCIS (customer information system), SpryEngage (customer portal), SpryMobile (mobile field service), and SpryIDM (interval data management).

Highlights our selection and partnership with LOGIS for SpryCIS (customer information system), SpryEngage (customer portal), SpryMobile (mobile field service), and SpryIDM (interval data management).

LOGIS provides technological solutions and support that help Minnesota’s local governments and the communities they serve thrive. In addition to its utility billing application offering, LOGIS offers software solutions that meet financial, human resources, public safety, permitting and inspections, GIS, and other critical needs, as well as a complete package of network services, including infrastructure and system design, security, and other managed services.

“We quickly recognized that LOGIS embodies the ideal membership for collaboration with SpryPoint. LOGIS employs a forward-thinking vision that invests in technology and software to provide best-in-class solutions that improve the lives of both its member’s employees and the local communities they serve,” Kyle Strang, SpryPoint CEO shared, “Through this partnership, member utilities within LOGIS can leverage a trusted relationship, alleviate operational challenges, and deliver an exceptional customer experience using SpryPoint’s suite of cloud-native products”.

Chris Miller, Executive Director of LOGIS commented, “When LOGIS began searching for a new utility CIS system, we conducted a comprehensive review of numerous solutions that might meet our business customers’ everyday needs. SpryPoint emerged as the only product that would replace our legacy system and provide enhanced capabilities that we had sought for many years. Our partnership with SpryPoint strategically positions us to help local communities thrive for the foreseeable future.”

LOGIS member projects are underway with the cities of Waconia and Maple Grove.

About LOGIS

Founded in 1972, LOGIS was created out of individual necessity but continued to grow and evolve through successful collaboration. In the late 1960’s and early 1970’s, local governments struggled to meet their technology needs due to high costs and a lack of software geared towards their unique environment. The solution was to combine resources from multiple government agencies to develop software that met those needs. LOGIS was created to carry out that objective. We understand local government because we are local government. We’re an extension of our members’ staff and helping them succeed is our number one priority.

LOGIS employs a diverse workforce with varied experience, skillsets, and perspectives. We’re committed to providing avenues for personal and professional growth, and opportunities for career advancement. Each employee is asked to participate in our planning processes to ensure member outcomes are improved, and our long-term strategies are fulfilled.

About SpryPoint

SpryPoint is the leading provider of software for public utilities, focusing on delivering innovative and efficient technologies to enable exceptional customer service while optimizing operations. With a robust product line that addresses everything from customer information systems to field service management, SpryPoint is at the forefront of the digital transformation in the utilities sector. To learn more about SpryPoint, please visit us at sprypoint.com, by phone at 1-855-879-7779 (855-TRY-SPRY) or info@sprypoint.com.

Media Contact

Emily Beardsley, SpryPoint, 1 855-879-7779, info@sprypoint.com, www.sprypoint.com

View original content:https://www.prweb.com/releases/local-government-information-systems-logis-selects-sprypoint-as-utility-solutions-provider-to-enhance-customer-experience-for-their-members-302292537.html

SOURCE SpryPoint

Continue Reading

Technology

Is Dynamic Navigation the Future of Implant Placement Technology?

Published

on

By

Recently published in the Journal of Oral Implantology, authors in this study evaluated the precision and predictability outcomes of conventional and dynamic navigation methods for computer-guided implant placements.

LAWRENCE, Kan., Oct. 31, 2024 /PRNewswire-PRWeb/ — Journal of Oral Implantology – Implant dentistry has become the face of modern dentistry when replacing missing teeth. The stability and longevity of implants have revolutionized the industry and allowed dentists to provide better options to patients needing prosthetic rehabilitation. Two approaches to computer-guided implant placements exist: static-guided and dynamic-navigation systems. The static-guided system is a free-hand technique when placing the implant, while the dynamic-navigation system uses computer imaging to guide the placement.

There is a dire need to conduct this research to evaluate the precision and predictability outcomes of conventional and dynamic navigation methods.

Researchers from Vinshu Dental College in Andhra Pradesh, India, and Sahyog Maxillofacial Center in Maharashtra, India, recently published a study in the Journal of Oral Implantology to assess the use of the static-guided system compared with the dynamic-navigation system. Lead author Gautami S. Penmetsa, MDS, and colleagues state, “Computer-aided implants, a more recent innovation in Implantology, have limited research literature. Hence, there is a dire need to conduct this research to evaluate the precision and predictability outcomes of conventional and dynamic navigation methods.”

Penmetsa et al. conducted a randomized controlled clinical trial in 40 patients needing zygomatic implants. Twenty patients were randomly assigned to a control group using the static-guided system and 20 to the dynamic-navigation system. Inclusion criteria included patients in good physical and oral health; exclusion criteria included poor health, smoking, restricted mouth opening, and a history of head/neck radiotherapy. Upon implant placement, the researchers compared the entry, apex, and angular deviations between both treatment groups.

The results showed statistically significant mean deviations at the entry site in the dynamic-navigation group. At the apex, there was more variation in the static group, and a higher accuracy level was found in the dynamic group regarding angular deviation. The researchers also compared both groups’ right- and left-side accuracy and precision and discovered better predictability for the dynamic group.

This clinical trial shows that the dynamic-navigation system outperformed the static-guided system regarding entry, apex, and angular deviation. These findings lead Penmetsa and colleagues to conclude, “Dynamic navigation technology has proven to be more effective in precision and accuracy, emphasizing that computer-aided implantology will be the future of implant dentistry.” They also note, “Despite the cost and learning curve associated with dynamic navigation technology, its superior predictability in accuracy and precision makes it essential for clinicians to master.”

Full text of the article “Comparative Evaluation of the Accuracy of Dynamic Navigation and Free Hand Methods During Zygomatic Implant Placement: A Randomized Controlled Trial,” Journal of Oral Implantology, Vol. 50, No. 5, 2024, is available at https://doi.org/10.1563/aaid-joi-D-23-00096.

About Journal of Oral Implantology

The Journal of Oral Implantology is the official publication of the American Academy of Implant Dentistry and the American Academy of Implant Prosthodontics. It provides valuable information to general dentists, oral surgeons, prosthodontists, periodontists, scientists, clinicians, laboratory owners and technicians, manufacturers, and educators. The JOI distinguishes itself as the first and oldest journal in the world devoted exclusively to implant dentistry. For more information about the journal or society, please visit: http://www.joionline.org/orimonline/?request=index-html.

Media Contact

Samantha Weinkauf, KnowledgeWorks Global Ltd., 1 785-289-2649, samantha.weinkauf@kwglobal.com

View original content:https://www.prweb.com/releases/is-dynamic-navigation-the-future-of-implant-placement-technology-302292535.html

SOURCE Journal of Oral Implantology

Continue Reading

Trending